Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Internal Medicine (Tokyo, Japan)|October 22, 2025
Endotracheal and Endobronchial Metastases in Epidermal Growth Factor Receptor Exon 19 Deletion Lung Adenocarcinoma: A Case Successfully Managed with Bronchoscopic Therapy and Sequential Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsMiho Fujiwara, Takahiro Baba, Kotaro Yamada, et al.
Cancer Science|February 27, 2026
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung CancerTadahiro Kuribayashi, Jun Nishimura, Sachi Okawa, et al.
Japanese Journal of Clinical Oncology|September 2, 2020
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patientsToshio Kubo, Hiromi Watanabe, Kiichiro Ninomiya, et al.
Plos One|October 26, 2023
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infectionEiki Ichihara, Kou Hasegawa, Kenichiro Kudo, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve <i>Egfr</i>-Mutant Lung Cancer with Non-Inflamed Tumor MicroenvironmentAtsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, et al.
Respiratory Research|February 8, 2022
Identification of targetable kinases in idiopathic pulmonary fibrosisHisao Higo, Kadoaki Ohashi, Shuta Tomida, et al.
International Journal of Clinical Oncology|February 5, 2025
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II studyKatsuyuki Hotta, Sho Saeki, Shinya Sakata, et al.
Internal Medicine (Tokyo, Japan)|September 11, 2024
Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation SuspensionTaichi Ozeki, Hisao Higo, Hiroki Omori, et al.
Lung|January 24, 2024
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)Nobuhiro Kanaji, Eiki Ichihara, Takaaki Tanaka, et al.
Cancer Science|July 28, 2018
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusionsYuka Kato, Kiichiro Ninomiya, Kadoaki Ohashi, et al.
Pageof 18